The European Society of Medicine published NDR's opinion piece Amyotrophic Lateral Sclerosis is a spectrum of diseases that needs a broad treatment approach. The editorial is support for our position that thymopentin in the form of FC-12738 can bring a major contribution to the ALS field because it is designed to regulate the cell danger response by natural innate immune pathways. It was Richards hope to bring such a treatment to those diagnosed with ALS. The human trial (in normal subjects) wrapped up with no issues. When the paperwork completes we will move into ALS patients. Richard would be pleased.
